← Leaderboards
Umesh Masharani
University Of California San Francisco
$598,867
Attributed
$598,867
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $221.9K · FY2005–07$250K$187.5K$125K$62.5K$0
'05
'06
'07
Funding mix
By agency
NIH$598,867 · 2
By mechanism
R21$596,210 · 1
M01$2,657 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Peter G Stock$42,550,391
- Qizhi Tang$8,696,514
- James Louis Rubenstein$5,966,949
- John K. Wiencke$22,119,904
- Sang-Mo Kang$2,017,044
Others in their field
Top investigators on “Insulin”
- Jeffrey P Krischer · University Of South Florida$605,714,892
- John M Lachin · George Washington University$153,440,346
- David M Nathan · Massachusetts Institute Of Technology$139,041,931
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$108,827,660
- Mark A Magnuson · Vanderbilt University$79,749,111
- Jose A Luchsinger · Columbia University Health Sciences$71,267,462
Research focus
InsulinAnimalsDisease /Disorder Prevention /ControlBiopsyChromiumChromium PicolinateClinical ResearchClinical Trial Phase IiCohortCoronary ArteriosclerosisCultured CellsDailyDiabetes Mellitus, Non-Insulin-DependentDiabetes Mellitus TherapyBaseEnrollmentEnzyme Linked Immunosorbent AssayGeneral PopulationGlucoseGlucose ToleranceGlucose UptakeGlut4 GeneHomeostasisAftercare
Grant awards (5)
Chromium and Insulin Resistance$184,925
R21 · FY2007 · AT · contact PI
Chromium and Insulin Resistance$221,910
R21 · FY2006 · AT · contact PI
Chromium and Insulin Resistance$189,375
R21 · FY2005 · AT
PHASE II MULTIDOSE TREATMENT OF TYPE 1 DIABETES MELLITUS WITH HOKT3GAMA1$1,467
M01 · FY2005 · RR
Phase II multidose treatment of type 1 diabetes mellitus with hOKT3gama1$1,190
M01 · FY2004 · RR